Ocugen, Inc. reported $4.6M of revenue over the trailing twelve months, −3.7% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $4.6M (to Q2 2026). Net income: −$82M, trailing twelve months to Q2 2026. Free cash flow: −$61M, trailing twelve months to Q2 2026. Operating margin: 1383%, trailing twelve months to Q2 2026.

OCGNOcugen, Inc.

Healthcare

$0.74-51% 1Y

$0.74

$0.7452 weeks$2.48

Latest close: a new 52-week lowOct 23, 2026what changed →

OCGN as reported

Ocugen, Inc. reported $4.6M of revenue over the trailing twelve months, −3.7% on the year before. 9 reported series are charted on this page, each one as filed.

$4.6M

Revenue, trailing twelve months · to Q2 2026 · −3.7% against the twelve months before

Net income: −$82M
Net income · +44% year on year · trailing twelve months to Q2 2026
Free cash flow: −$61M
Free cash flow · +17% year on year · trailing twelve months to Q2 2026
Operating margin: 1383%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for OCGN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$4.6M	−3.7%	Q2 2026
Net income	−$82M	+44%	Q2 2026
EPS	−$0.18	n/a	Q2 2024 · 8 quarters behind
Operating margin	1383%	n/a	Q2 2026
Net margin	1277%	n/a	Q2 2026
ROE	−499%	n/a	Q2 2026
ROA	−115%	n/a	Q2 2026
ROIC	1476%	n/a	Q2 2026
Free cash flow	−$61M	+17%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.